Rentosertib — Insilico Medicine · idiopathic pulmonary fibrosis
The furthest along by a clear margin, and the first drug where AI picked both the target (TNIK) and the molecule. Phase IIa in Nature Medicine (71 patients, 12 weeks) showed a +98.4 mL lung-function signal at the top dose. Phase III started in 2026 — 320 patients, 52 weeks. IPF has no cure today; even success here would first be a treatment, not yet a cure.